FCA sets aside order for price information production of previously patented medicine
The Federal Court of Appeal has allowed an appeal in a case related to the Patented Medicine Prices Review Board ordering a company to provide pricing information on its medicine six...To view the full article, register now.
Already a subscriber? Click here to view full article